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Abstract 
 
Background 
Temozolomide shows activity against medulloblastoma, the most common malignant 
paediatric brain tumour. PARP inhibitors enhance temozolomide activity in extra-
cranial adult  and paediatric human malignancies.  
Methods 
We assessed the effect of AG-014699, a clinically active PARP inhibitor, on 
temozolomide-induced growth inhibition in human medulloblastoma models. 
Pharmacokinetic, pharmacodynamic and toxicity assays were performed in tumour-
bearing mice. 
Results 
Sensitivity to temozolomide in vitro was consistent with MGMT and DNA mismatch 
repair (MMR) status; MGMT+ MMR+ D384Med cells (temozolomide GI50= 220 µM), 
representative of most primary medulloblastomas, were sensitized 4-fold by AG-
014699, MGMT- MMR+ D425Med cells were hypersensitive (GI50=9 µM) and not 
sensitized by AG-014699, while MGMT+ MMR- temozolomide-resistant D283Med 
cells (GI50= 807 µM) were sensitized 20-fold.  In xenograft models, co-administration 
of AG-014699 produced an increase in temozolomide-induced tumour growth delay 
in D384Med xenografts.  Consistent with the in vitro data, temozolomide caused 
complete tumour regressions of D425Med xenografts, while D283Med xenografts 
were relatively resistant. AG-014699 was not toxic, accumulated and reduced PARP 
activity ≥75% in xenograft and brain tissues,.   
Conclusion 
We demonstrate for the first time CNS penetration and inhibition of brain PARP 
activity by AG-014699. Together with our in vitro chemosensitisation and toxicity 
data, these findings support further evaluation of the clinical potential of AG-014699-
temozolomide combinations in intra-cranial malignancies.  
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Introduction  
Medulloblastoma is the most common malignant paediatric brain tumour and 
accounts for almost 10% of all childhood cancer deaths. The clinical outcome for 
patients with medulloblastoma is variable and overall ~40% of children with 
medulloblastoma will die of their disease (Pizer and Clifford, 2008; 2009). Current 
therapies for medulloblastoma comprise maximal surgical resection, craniospinal 
irradiation and chemotherapy. The use of these combined modalities has led to long-
term survival rates of ~80% in standard risk cases and ~40-60% in high risk cases 
(infants <3yrs or metastatic disease at presentation). However, the development of 
relapsed, drug-resistant disease is common, particularly in high-risk cases (~50%) 
and long-term side-effects associated with these therapies including intellectual and 
neuro-endocrine impairment with craniospinal irradiation with (reviewed in Pizer and 
Clifford, 2009). New therapeutic approaches, particularly those which may result in 
improved therapeutic outcome and reduced long-term sequelae, are clearly 
warranted.  
Temozolomide shows significant single-agent activity in adult oligodendrogliomas 
and high-grade astrocytomas and evidence of activity in pre-clinical medulloblastoma 
models (Friedman et al, 1995, Middlemas et al, 2000, Macdonald, 2001 and van den 
Brent et al, 2003).  Recently Phase I and II trials of temozolomide, using a variety of 
schedules, have been undertaken in paediatric brain tumour patients, including 
medulloblastoma (reviewed in Barone et al, 2006). The maximum tolerated dose and 
dose-limiting toxicities in paediatric patients appear to be similar to those in adults, 
and encouraging responses have been observed against medulloblastoma (Baruchel 
et al, 2006, Nicholson et al, 2007 and Wang et al, 2009), supporting the further 
investigation of temozolomide in this disease. 
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DNA damage signalling and repair pathways are novel and promising targets for 
improved cancer therapy, particularly with regard to radio- and chemosensitisation. 
Genomic instability, which often results from DNA damage signalling and repair 
defects, is a common characteristic of cancer. Such defects can render the cancer 
cell more dependent on complementary signalling and repair pathways, which are 
often upregulated. These upregulated pathways can compromise the efficacy of DNA 
damaging anticancer agents and represent a novel  therapeutic target to specifically 
sensitise cancer cells (reviewed in Curtin, 2007). Resistance to temozolomide 
therapy has been associated with high levels of methylguanine methyltransferase 
(MGMT) and defects in mismatch repair (Curtin et al, 2004). In adult glioma patients, 
sensitivity to temozolomide is associated with methylation of the MGMT promoter 
(Hegi et al, 2005). Attempts to modulate temozolomide resistance through inhibition 
of MGMT with co-administration of O6-benzylguanine have not lived up to their pre-
clinical promise in adult brain tumour patients (reviewed in Curtin, 2007). This 
approach has also been tested in the Phase I setting in children, but the numbers are 
too small to determine if success is likely to be greater (Broniscer et al, 2007). In the 
preclinical setting, defects in DNA mismatch repair (MMR) are associated with 
resistance to temozolomide, which is not overcome by MGMT inhibition (Curtin et al, 
2004, Cheng et al, 2005). In the Phase I O6-benzylguanine combination study, 
microsatellite instability, an indication of defective MMR, was observed in 4 of the 6 
medulloblastoma patients.  The MGMT status of primary medulloblastomas is 
controversial, with variable estimates in the literature, although in general MGMT 
defects appear relatively uncommon (reviewed in Lindsey et al, 2005). Similarly, in 
other studies, MMR defects occur only in a small subset of medulloblastomas (Viana-
Pereira et al, 2009).   
An alternative strategy to enhance temozolomide activity is to inhibit poly(ADP-
ribose) polymerase-1and -2 (PARP-1 and PARP-2).  These enzymes are activated 
CNS penetration and chemosensitisation by AG-014699 
 5
by DNA single strand and double strand breaks (SSB and DSB) and promote their 
repair through the relaxation of chromatin and recruitment of other repair proteins. 
We have previously shown that PARP inhibitors can restore temozolomide sensitivity 
to MMR-defective cells (Curtin et al, 2004), and sensitise tumour cells and 
xenografts, including models competent for MMR and MGMT, to temozolomide 
(Calabrese et al. 2004). The first PARP inhibitor to enter clinical trial for cancer 
therapy was AG-014699, in combination with temozolomide (Plummer et al, 2008), 
which was selected on the basis of preclinical data in models of adult human 
malignancies (Thomas et al, 2007). AG-014699 has favourable pharmacokinetics 
and causes profound and sustained inhibition of PARP activity in surrogate normal 
tissues (peripheral blood lymphocytes: PBLs) and tumours (Plummer et al, 2008). In 
the Phase II setting, AG-014699 doubled the reported response rate to temozolomide 
(Plummer et al, 2006). We have recently been investigating the potential of AG-
014699 in models of paediatric malignancies and found that it increased the efficacy 
of temozolomide and topotecan in neuroblastoma cells and xenografts (Daniel et al, 
2009).  
We wished to investigate if AG-014699 could be beneficial for the treatment of 
intracranial tumours, using medulloblastoma as a model. CNS tumours can be more 
difficult to treat because of the blood-brain barrier (BBB) that limits drug uptake into 
central nervous system (CNS) tissues. The BBB is a physical and biochemical 
impediment to the transport of drugs into the CNS by virtue of highly impenetrable 
vascular endothelial cells and an abundance of drug efflux pumps (reviewed in 
Deeken and Loscher, 2007). In general, for good CNS penetration drugs should have 
few hydrogen bond donors and positive charges, lower polar surfaces, reduced 
flexibility and be <400 Da in size (Deeken and Loscher, 2007). AG-014699 is the 
phosphate salt of the active compound AG014447, which has a molecular weight of 
323 Da, pKa of 9.6 and a clogD of 0.7 (Thomas et al, 2007).  It is likely to exist as a 
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protonated amine at physiological pH and has some polar functionalities that may not 
favour CNS penetration. The BBB has been hypothesised to be less intact in primary 
and metastatic brain tumours, at least in the case of large tumours, where the 
physiology of the endothelial cells is different from the rest of the brain (reviewed in 
Daniel et al, 2009).  However, a number of other PARP inhibitors, including ones with 
similar structure to AG014447, have been shown to penetrate and have biological 
activity in the brain in pre-clinical models of adult malignancies (Tentori et al, 2003, 
Hattori et al, 2004 and Donawho et al, 2007). Recent clinical trials of the PARP 
inhibitor, olaparib, showed evidence of regression of in a brain metastasis in one 
patient (Fong et al, 2009). Temozolomide shows good CNS penetration, and uptake 
into human gliomas was higher than the surrounding normal brain, due to breakdown 
of the BBB and possibly tumour-induced angiogenesis (Rosso et al, 2009). 
Furthermore, radiotherapy can also disrupt the BBB (reviewed in Deeken and 
Loscher, 2007). However, it may be hypothesised that, for smaller tumours including 
the CNS metastatic deposits commonly associated with medulloblastoma relapse, 
the BBB may still be intact. It is therefore important to determine if AG-014699 can 
penetrate CNS tissues. 
We report here the pre-clinical assessment of AG-014699, in vitro and in vivo in 
human medulloblastoma models. Our data demonstrate the distribution of AG-
014699 and inhibition of PARP in CNS tissue for the first time and show the clear 
potential of PARP inhibitors in combination with temozolomide for the improved 
therapy of medulloblastoma.  
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Materials and Methods 
Materials 
Temozolomide was a gift from Cancer Research UK, London, U.K., and AG-014699 
(PO4 salt of AG-014447, now also called PF-01367338) was a gift from Pfizer 
Oncology, La Jolla, CA, USA. Temozolomide was dissolved in dimethyl sulfoxide 
(DMSO) prior to addition to cell cultures at a final concentration of 0.5% (v/v) DMSO. 
For in vivo evaluation, temozolomide was dissolved in saline immediately before 
administration. 10H mouse monoclonal antibody to ADP-ribose polymers was a kind 
gift from Dr Alexander Burkle, University of Konstanz, Germany. Other chemicals and 
reagents were obtained from Sigma (Poole, U.K.), unless otherwise stated. 
Cell Lines and Culture 
Three medulloblastoma cell lines were selected for study. D384Med and D425Med 
were kind gifts from Dr.D.Bigner (Duke University, USA). D283Med was obtained 
from the American Type Culture Collection (Manassas USA). Published cell line 
karyotypes and genetic features were confirmed in each cell line prior to use; all 
three lines harboured genetic lesions consistent with primary medulloblastomas 
(Langdon et al, 2006).  All three medulloblastoma cell lines were maintained using 
standard methods, in Dulbecco’s modified eagle medium (DMEM) containing 20% 
fetal calf serum (Life Technologies, Paisley, U.K.), and were confirmed to be 
Mycoplasma-free. 
Cell Line Protein Expression 
Protein lysates were prepared from each cell line using standard methods and 
examined for the presence of the PARP-1 protein (H-250 anti-PARP-1 antibody, 
Santa Cruz Biotechnology, Heidelberg, Germany) and α-tubulin control using 
CNS penetration and chemosensitisation by AG-014699 
 8
western blot analysis (50µg protein loaded per well). Lysates were also blotted for 
cell line expression of MGMT and the mismatch-repair (MMR) proteins MLH1, MSH2, 
MSH3, MSH6 and PMS2 (All mouse monoclonal antibodies, BD Biosciences 
Pharmingen, Oxford, UK). 
Inhibition of cellular PARP activity by AG-014699 
Inhibition of PARP activity in 5000 exponentially-growing D283Med cells was 
measured following treatment with a range of AG-014699 concentrations (0 - 1 µM), 
in comparison with DMSO-only controls. Maximally-stimulated PARP activity was 
measured in replicate samples (n≥3) of permeabilised cells by immunological 
detection of the amount of poly(ADP-ribose) (PAR) formed, using 10H anti-PAR Ab, 
during a 6 min incubation with NAD+ and oligonucleotide (substrate and activator) by 
reference to a PAR (Biomol Research Labs, Plymouth, PA, USA) standard curve 
using a GCLP-validated assay described previously (Plummer et al, 2005) .  
In Vitro Growth Inhibition and Cytotoxicity Assays 
Cell growth inhibition was estimated in exponentially growing D425Med, D283Med, 
and D384Med cells in 96-well plates. Seeding densities of 1x103, 3x103 and 3x103 
cells, respectively, ensured exponential growth for the duration of the experiment. 24 
hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, cells were 
exposed to varying concentrations of temozolomide, as described in the results, in 
the presence or absence of 0.4 µM AG-014699, a concentration previously shown to 
enhance temozolomide cytotoxicity in adult tumour cell lines (Thomas et al, 2007). 
After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture (equivalent to 
approximately 3 cell divisions), the cell viability was quantified using an XTT cell 
proliferation kit assay (Roche, Mannheim, Germany), according to the manufacturer’s 
instructions. Cell growth was expressed as a percentage in relation to DMSO or 0.4 
µM AG-014699 alone controls. The concentration of temozolomide, alone or in 
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combination with AG-014699, that inhibited growth by 50% (GI50) was calculated 
from computer-generated curves (GraphPad Software, San Diego, CA). The 
potentiation factor50 (PF50) is defined as the ratio of the GI50 of temozolomide in the 
presence of AG-014699 to the GI50 of temozolomide alone. All data were from at 
least three independent experiments.  
Establishment of D425Med, D283Med and D384Med tumour xenografts. 
All of the in vivo experiments were reviewed and approved by the relevant 
institutional animal welfare committees, and performed according to national law. 
Female athymic nude mice (CD1 nu/nu, Charles River, Margate, UK) used for anti-
tumour studies were maintained and handled in isolators under specific pathogen-
free conditions. D425Med, D283Med and D384Med (1 x 107 exponentially growing 
cells per mouse, harvested and implanted in growth media) xenografts were 
established by sub-cutaneous implantation into CD-1 nude mice. Prior to use in 
experiments, xenograft establishment was defined as when two dimensional calliper 
measurements of tumours reached approximately 5 x 5 mm. Treatment was initiated 
when sufficient number of mice had established tumours to allow randomisation into 
treatment groups: day 17 for D425 Med, day 26 for D384 Med and day 32 for D283 
Med. Tumour-bearing mice were killed 100 days after start of treatment or when two 
dimensions of a tumour xenograft reached 10 mm or one dimension reached 15 mm, 
whichever was the soonest. 
AG-014699 Pharmacokinetics and Pharmacodynamics in mouse plasma, brain 
and D283Med Tumour Xenografts 
One or four daily doses of PARP inhibitor AG-014699 (1 mg/kg intraperitoneally (i.p.)) 
were given to CD-1 nude mice bearing established D283Med xenografts. At 0.5, 2, 6 
and 24 hours after the initial or fourth daily dose of AG-014699, three animals per 
time point were bled by cardiac puncture under general anaesthesia, then killed. 
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Plasma was separated from the blood samples using standard methods and stored 
at -80˚C. The brains and tumours were removed, snap frozen in liquid nitrogen and 
stored at -80˚C prior to analysis. Blood, tumour and brain tissue were removed from 
three untreated control animals and processed in the same way. 
AG-014699 Distribution in Plasma, Brain and Tumour Xenograft Samples  
AG-014699 is the phosphate salt of AG014447 and rapidly liberates the parent drug 
following injection. The concentration of AG014447 was determined in plasma and 
tissue homogenates (1:4 w/v in PBS) of brain and tumour after protein precipitation 
with acetonitrile by liquid chromatography/mass spectrometry/mass spectrometry 
(LC/MS/MS) using a turbo ion spray interface and multiple reaction monitoring in the 
positive ion mode (API 4000, Applied Biosystems, Warrington, Cheshire UK) and a 
deuterated internal standard as described previously (Plummer et al, 2008). The 
lower limit of quantitation was 1 ng/ml. Plasma pharmacokinetics of AG014447 were 
analyzed using a non-compartmental approach in WinNonlin version 5.2. 
Pharmacodynamics in brain and tumour tissue: PARP-1 Activity Assays 
PARP activity was determined in homogenates of subcutaneous D283Med 
xenografts and brain tissue (see above).  Maximally-stimulated PARP activity was 
measured in replicate samples (n≥3) of a 1:1,000 dilution of the homogenate as 
described for permeabilised D283Med cells (see above). Data were calculated as 
pmol PAR/mg protein by reference to the PAR standard curve and protein content of 
the sample and expressed as a percentage of the corresponding tissue from the 
saline-treated control animals. The mean PARP activity in xenograft and brain 
samples taken at each time point  was expressed as a percentage of the mean 
PARP activity of control xenografts from untreated mice (n=3).  
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Tumour Growth Inhibition In Vivo 
CD-1 nude mice bearing palpable, established subcutaneous D425Med, D283Med 
and D384Med xenografts were treated with normal saline (control animals), 
temozolomide (68 mg/kg p.o.) or AG-014699 (1 mg/kg i.p.) alone or in combination, 
daily for 5 days (five mice per group). For drug combinations, AG-014699 was 
administered immediately after administering temozolomide. Tumour volumes, 
determined from two-dimensional caliper measurements and the equation a2 x b/2 
(where a is the length and b is the width of the tumour), were monitored for the 
experimental period (up to100 days), and are presented for each group of mice as 
median relative tumour volume (RTV) values. RTV1 is the tumour volume on the 
initial day of treatment (day 0), and RTV4 is the tumour volume 4 times that on the 
initial day of treatment. Tumour growth delay is defined as the time to RTV4 in drug-
treated mice compared with the time to RTV4 in control (vehicle alone) mice. Median 
tumour volume is shown, rather than the mean, as this is generally accepted as the 
most statistically reliable representation of the average growth rate of tumours in a 
small group of mice, where a normal distribution of tumour volumes cannot be 
assumed. Tumour growth delay (TGD) was calculated as (median time to RTV4 in 
treated group - median time to RTV4 in control group). Percentage enhancement 
was calculated as 100 x (TGD TMZ+AG/TGD TMZ alone) – 100 (Calabrese et al. 
2004). 
 
Results 
AG-014699 and PARP-1 Inhibition in Permeabilised Medulloblastoma Cells 
AG-014699 is a potent inhibitor of purified full-length human PARP-1 (Thomas et al 
2007). We assayed PARP-1 activity in permeabilised D283Med cells after AG-
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014699 treatment. AG-014699, at concentrations of 0.1, 0.4 and 1 µM inhibited 
PARP-1 activity by 81.1%, 96.8 and 97.1%, respectively. All previous cellular 
chemosensitisation studies with this class of PARP inhibitor, including AG-014699 
have used a concentration of 0.4 µM (Calabrese et al, 2004, Thomas et al, 2007). As 
this concentration also caused almost total inhibition of the PARP activity in 
medulloblastoma cells, we used a concentration of 0.4 µM AG-014699 to study the 
chemosensitisation of temozolomide, enabling comparison with previous data.  
Cell line expression of inhibition target and DNA repair pathway proteins 
All three cell lines selected for study expressed PARP-1 by Western blotting (Figure 
1). D384Med also clearly expressed MGMT and the mismatch-repair (MMR) proteins 
MLH1, MSH2, MSH3, MSH6 and PMS2 indicating competence in these pathways 
implicated in temozolomide sensitivity. However, two of the cell lines were found to 
be compromised in the expression of some of these proteins. D425Med lacked 
MGMT and D283Med was deficient in MLH1 and had barely detectable PMS2, 
indicating MMR dysfunction.  
Potentiation of Temozolomide Induced Growth Inhibition by AG-014699 
We measured the growth of cells exposed to increasing concentrations of 
temozolomide alone or in combination with 0.4 µM AG-014699 continuously, over a 
period of three cell doublings. Representative growth inhibition curves of D425Med 
(Figure 2A), D283Med (Figure 2B) and D384Med (Figure 2C) are shown. Pooled GI50 
data for temozolomide with and without AG-014699 from at least three independent 
experiments for each of the three cell lines are shown in Table 1.  AG-014699 alone 
was not growth inhibitory at the concentration used (0.4 µM) (data not shown). 
Temozolomide alone caused a concentration-dependent inhibition of growth in all 
three cell lines. Cell lines exhibited variable levels of sensitivity to temozolomide 
alone. The MGMT deficient D425Med cells were hypersensitive to temozolomide, 
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and the MMR-defective D283Med cells were nearly 100x less sensitive, as expected. 
The D384Med cells, which were proficient in both pathways displayed intermediate 
sensitivity. There was also considerable variation in the degree of chemosensitisation 
by AG-014699 between the cells, with almost 20-fold sensitisation of the MMR-
defective, D283Med, cells compared to >3-fold sensitisation in the MMR and MGMT 
competent D384Med cells, but no sensitisation of the MGMT-deficient, D425Med, 
cells. 
AG-014699 levels in Plasma, Brain Tissue and D283Med Tumour Xenografts 
A dose of 1 mg/kg AG-014699 daily x 5 has previously been shown to be non-toxic 
and sufficient for profound chemosensitisation of human colon and neuroblastoma 
cancer xenografts to temozolomide (Thomas et al, 2007, Daniel et al, 2009). 
Therefore we selected this dose to investigate chemosensitisation of 
medulloblastoma xenografts. Prior to undertaking these studies, we determined the 
distribution of the PARP inhibitor in the plasma, and to brain and tumour tissue, 
following a single dose and 4 daily doses of 1 mg AG-014699/kg i.p. in mice bearing 
D283-Med sub-cutaneous xenografts. We measured concentrations of AG-014447 at 
either 0.5, 2, 6 or 24 hours after dosing (3 mice/time-point).  
After the first dose of AG-014699 (Fig 3 A(i)) a peak plasma concentration of 56 ± 13 
ng/ml (172 ± 39 µM) AG-014447 was detected at the earliest time point after 
injection. Thereafter the levels decreased rapidly, such that at 24 hr they were below 
the level of quantitation.  
Levels in the tumour were higher than in the plasma at all time points (Figure 3A), e.g 
230 to 1510 nM in the tumour compared to 131 to 209 nM in plasma at 30 min. There 
was also significant and prolonged retention within the tumour, such that at 24 hr 
after injection, levels of between 74 and 196 nM were still detectable. Surprisingly, 
given its physical and chemical properties, signifi
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detected in the brain tissue. Although these were initially lower than those in the 
plasma (20-40 nM at 30 min) there was some degree of retention such that at 24 hr 
the levels were up to 10-fold higher than in the plasma (1-30 nM in brain compared 
with 1.9 to 2.4 nM in plasma). After the 4th daily dose of AG-014699 (Fig 3A(ii)) peak 
plasma AG014447 concentrations were similar to those following a single dose. 
Levels in the brain were only marginally greater than plasma levels at 6 hr. However, 
high concentrations (639-932 nM) were retained in the tumour for the entire period. In 
the plasma, AUCs (26.4 and 21.9 µM.min on days 1 and 4) and half-life (299 and 254 
min) were similar to those reported previously (Thomas et al, 2007). The AUCs in the 
brain (37.0 and 14.7 µM.min on days 1 and 4) were comparable to those in plasma, 
while AUCs in tumour were substantially higher (582.0 and 509.6 µM.min).  
Consistent with the AG014447 distribution data, PARP activity was suppressed in 
both brain and tumour tissue following administration of AG-014699. In the brain, 
PARP activity was reduced by around 75% for the first 2 hours, recovering gradually 
thereafter, such that it was approximately 40% reduced at 24 hr (Figure 3B(i)). After 
the 4th daily dose however, there was less suppression and more rapid recovery such 
that near normal activity was detected at 24 hr (Figure 3B(ii)). This presumably 
reflects the lower AUC of the drug in this tissue after the 4th dose. In contrast, in the 
tumour, inhibition of PARP activity was slightly delayed, reaching a nadir of around 
75% reduction at 6 hr post injection, which was similar (barring obvious outlier data) 
after the 1st and 4th dose (Figures 3C (i and ii)). The modest recovery at 24 hr did 
appear greater after the 4th dose than the 1st, however. 
Efficacy of temozolomide with AG-014699 in Human Tumour Xenografts 
We examined the effect of AG-014699 on the antitumour activity of temozolomide in 
mice bearing established subcutaneous D425Med, D283Med or D384Med 
xenografts. Mice were treated daily for 5 days with either vehicle control alone, AG-
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014699 alone (1 mg/kg i.p.), TMZ alone (68 mg/kg p.o.) or the combination of TMZ 
(68 mg/kg p.o.) + AG-014699 (1 mg/kg i.p.) data are summarised in Table 2. 
At 1 mg/kg daily x5, AG-014699 alone did not cause any marked toxicity or affect 
tumour growth compared to vehicle only controls. The D425Med cells grew relatively 
slowly (median time to RTV 4 = 19 days) and, as expected from the in vitro data, 
were very responsive to temozolomide alone with complete tumour regressions seen 
in all mice (Figure 4A). These regressions were sustained for the designated 
experimental period (100 days) in 2/5 of the mice. Co-administration of AG-014699 
with temozolomide also resulted in complete tumour regressions in all mice, of which 
3/5 were sustained throughout the experiment. The MMR defective D283Med 
xenografts grew very rapidly (median time to RTV4 = 7 days) and showed very little 
response to temozolomide alone (tumour growth delay of only 2 days) with no 
regressions observed in any mice (Figure 4B). In contrast to the pronounced in vitro 
sensitisation, co-administration of AG-014699 only increased this tumour growth 
delay to 2.5 days. The D384Med xenografts, proficient in both MGMT and MMR 
pathways of DNA repair, grew at an intermediate rate (median time to RTV4 = 16 
days). Temozolomide alone caused a significant tumour growth delay (p=0.016), 
extending the time to RTV4 to 44.5 days (Figure 4C), and the combination with AG-
014699 the time to RTV4 was 62 days. Thus the temozolomide-induced tumor 
growth delay of 28.5 days was extended to 46 days by co-administration of AG-
014699, equivalent to a 61% increase in efficacy, however, this was not quite 
significant (p = 0.11 Mann-Whitney test). There was one transient complete response 
seen in both the temozolomide alone and the temozolomide+AG-014699 groups. 
Temozolomide alone caused a modest (5 ± 4%), but statistically significant, weight 
loss relative to control (p=0.0006, unpaired t-test). AG-014699 was not toxic per se (1 
± 1% body weight loss), but caused a modest, but significant, enhancement of 
temozolomide-induced body weight loss (10 ± 6% weight loss: p=0.013, unpaired t-
CNS penetration and chemosensitisation by AG-014699 
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test). 
 
Discussion 
In the work described here we sought to address the need for new therapeutic 
approaches to improve outcome in medulloblastoma.  Temozolomide shows good 
activity in adult glioblastomas (Mrugala et al, 2008) and encouraging data are 
emerging from Phase I and II studies in paediatric intra-cranial malignancies, 
including medulloblastoma (Barone et al, 2006, Baruchel et al, 2006, Nicholson et al, 
2007 and Wang et al, 2009). We assessed the efficacy of temozolomide alone, and 
in combination with the PARP inhibitor AG-014699 in medulloblastoma, using three 
models (D384 Med, D425 Med and D283 Med), which are genetically representative 
of the primary disease (Langdon et al, 2006).  We also investigated 
pharmacokinetics, pharmacodynamics and toxicity of AG-014699, and demonstrate 
for the first time uptake into CNS and significant and sustained PARP inhibition in 
brain tissue. 
We initially investigated in our models the status of molecular pathways implicated in 
the modulation of temozolomide sensitivity (i.e. DNA mismatch repair (MMR) and 
MGMT (Middlemas et al, 2000)).  Our cell lines modeled closely the diversity 
observed in primary medulloblastomas; D384 Med cells were proficient for all 
proteins tested, indicating they reflect the vast majority of primary medulloblastomas, 
in which MMR deficits (observed in ~10% of cases (Viana-Pereira et al, 2009)) and 
MGMT hypermethylation (~25% of cases (Lindsey et al, 2005)) are relatively 
uncommon.  Data for our other cell lines were consistent with their relevance as 
models of primary cases associated with MMR (D283 Med) and MGMT (D425 Med) 
deficiency.  In subsequent efficacy testing, the MGMT-deficient D425Med cells were 
very sensitive to temozolomide both in cell cultures and as xenografts, being nearly 
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25x more sensitive than the MGMT-proficient D384Med cells in culture, and showing 
complete tumour regressions in response to temozolomide alone in in vivo 
experiments. The sensitivity of D425Med to temozolomide alone may limit the 
usefulness of this cell line in assessing sensitization by inhibition of PARP.   
Previous studies in paediatric xenografts have also concluded that MGMT status is 
the major determinant of sensitivity to temozolomide, but that MMR defects also 
confer resistance (Middlemas et al, 2000). This was clearly illustrated in our panel by 
MMR-defective D283Med cells, which were nearly 4x less sensitive to temozolomide 
than D384Med cells and xenografts derived from these cells showed barely any 
response to temozolomide therapy. In cell culture experiments AG-014699, at a 
concentration that inhibited PARP by >95%, did not enhance temozolomide 
sensitivity in the MGMT-defective cells, but caused a striking 20-fold enhancement in 
the MMR-defective D283Med cells. These observations are in line with our previous 
observations in adult human cancer cell lines (Curtin et al, 2004, Calabrese et al, 
2004, Thomas et al, 2007).  These data reflect the molecular pathology of the cells 
and hence the relative contribution that O6-methylguanine and N7-methylguanine and 
N3-methyladenine (that are repaired by PARP-dependent processes) make to the 
overall cytotoxicity of temozolomide in the individual cell lines.  
In the in vivo chemosensitisation studies, co-administration of AG-014699 caused an 
approximately 60% increase in temozolomide-induced tumour growth delay in the 
DNA repair protein-competent D384Med xenografts but, due to the small sample 
number, the effect was not significant (p=0.11). In comparison, the D425Med 
tumours grew relatively slowly and responded well to temozolomide alone, with all 
mice showing complete tumour regressions, 2 of which were sustained until the 
termination of the experiment at 100 days. Xenografts from MGMT-deficient SW620 
cells show similar sensitivity to temozolomide alone but are sensitized further by 
AG14361 and AG-014699 (Calabrese et al, 2004, Thomas et al, 2007), most 
CNS penetration and chemosensitisation by AG-014699 
 18
probably because of the vasoactivity of these PARP inhibitors (Ali et al 2009). We 
had therefore expected to see potentiation of temozolomide antitumour activity in 
D425Med tumours by AG-014699. The number of complete regressions persisting to 
the end of the experiment was 3/5 in the temozolomide + AG-014699 group, 
compared to 2/5 in the temozolomide alone. On the basis of the small sample size, 
this cannot be considered significant but is nevertheless encouraging.  The lack of 
sensitization by AG-014699 of the anti-tumour effect of temozolomide in MMR-
defective D283Med xenografts was surprising, given the degree of potentiation seen 
in vitro.  The lack of effect of AG-014699 in the D283Med xenografts was not due to 
PK/PD limitations as accumulation of AG0144447 and substantial PARP inhibition 
was demonstrated in the tumours. MMR defects are observed in only a minority of 
medulloblastomas and the lack of synergy in this model does not undermine the 
rationale for combining PARP inhibitors with temozolomide.  Thus, in summary, we 
propose that the D384Med model most faithfully reflects the clinical situation in the 
majority of medulloblastoma cases. The indication of chemosensitisation observed in 
this model is therefore encouraging and warrants further investigation in a wider 
panel of MMR and MGMT competent medulloblastoma models.   
We have not previously determined the CNS penetration of AG014447, the free drug 
of which AG-014699 is the phosphate salt, nor its inhibition of PARP activity in the 
brain. We saw clear evidence of AG014447 penetration into brain tissue, and 
accompanying evidence of PARP inhibition, in mice with an intact BBB.  PARP 
activity in the brain was higher than expected for a non-dividing tissue, with the 
activity being in the range 88-106 pmolPAR/mg protein/ min. Although significantly 
lower than that detected in the associated tumour xenografts (1,402-3,236 
pmolPAR/mg protein/min), it was comparable with the activity detected in normal 
mouse liver and kidney (98 – 106 pmolPAR/mg protein/min in livers, 69 - 76 
pmolPAR/mg protein/min in kidneys unpublished observations). Although 
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concentrations of AG014447 achieved in the brain (20-60 nM) were lower than were 
used for in vitro chemosensitisation, the inhibition of PARP activity over the 24 hr 
period was 50-80%. This level of inhibition is in general agreement with the 80% 
inhibition of activity seen in permeabilised cells exposed to 100 nM AG-014699, and 
is sufficient to cause in vivo chemosensitisation in models of both adult and 
paediatric malignancies (Calabrese et al, 2004, Daniel et al, 2009). Importantly, the 
peak plasma level in mice treated with AG-014699 at 1 mg/kg was 42-68 ng/ml, 
which is approximately 1/10th the concentration in patients treated with the 
recommended Phase II dose of 12 mg/m2 (473-675 ng/ml). Therefore, higher drug 
levels and greater PARP inhibition should be achievable in the brains of patients 
treated with a safe dose of AG-014699. The observed accumulation of AG014447 in 
xenografted medulloblastomas, which is consistent with our data for other tumour 
types coupled with a potentially compromised blood-brain tumour barrier suggests 
that drug accumulation in the tumours may be even higher. Further investigations in 
orthotopic or spontaneous transgenic models of medulloblastoma could provide 
useful insights in this regard although the limitations of these models as 
representative of primary tumours and an intact blood-brain barrier must also be 
taken into account.  
Several PARP inhibitors have been shown to penetrate CNS tissue and to have a 
pharmacological effect, either in terms of an enhancement of the antitumour activity 
of temozolomide against intracranial tumours, or reduction in focal ischemia in a 
stroke model (Tentori et al, 2003, Hattori et al, 2004, Cheng et al, 2005 and Donawho 
et al 2007). Indeed, one of the indications of PARP inhibitors is in the reduction of 
brain tissue damage following stroke (Jagtap and Szabo, 2005). However, to the best 
of our knowledge, this is the first time that inhibition of PARP activity in the brains of 
mice treated with a PARP inhibitor has been demonstrated. 
CNS penetration and chemosensitisation by AG-014699 
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In summary, the data we present here shows encouraging enhancement of 
temozolomide activity in pre-clinical cell line models of medulloblastoma, 
representative of the spectrum of sensitivity to single-agent temozolomide. 
Furthermore, following a non-toxic dose of AG-014699, good CNS penetration and 
correspondingly substantial inhibition of PARP activity in nervous tissue, was 
observed in association with AG-014699 plasma levels 1/10th of those detected in 
patients treated with the recommended Phase II dose, and without significant toxicity. 
Further validation of these observations in a wider range of cell lines and in 
orthotopic models are required before a clinical evaluation of AG-014699 in 
combination with temozolomide for intracranial malignancies would be indicated. 
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Table 1. Growth inhibition by temozolomide and sensitisation by AG-014699 
Cell line GI50 Temozolomide 
(µM) 
GI50 Temozolomide + 
AG-014699 (µM) 
PF50 
D425Med 9.3 ± 7.5 a 13.3 ± 3.2 0.7 ± 0.4 
D283Med 807 ±239 42 ± 15** 19 ± 4.7 
D384Med 220 ± 42 60  ± 13* 3.8 ± 1 
 
a
 Data are means and standard deviation of 3 independent experiments of the type 
shown in Figure 2.  
* significantly different from temozolomide alone (p =0.003 Student’s 2-tailed t test) 
** significantly different from temozolomide alone (p = 0.005 Student’s 2-tailed t test) 
  
Table 2. Toxicity and efficacy of temozolomide and AG-014699 in Medulloblastoma xenografts 
Xenograft Treatment Median nadir body 
weight (% starting 
weight) 
Median time to RTV4 
(days) 
Tumour growth 
delay (days)  
(% enhancement) 
Complete 
Regressions 
D425Med Control 98 19  0/5 
AG-014699 98 15.5  0/5 
TMZ 96 >100 >81 2/5 
Combination 95 >100 >81 (NM) 3/5 
  
    
D283Med Control 98 7  0/5 
AG-014699 100 8 1 0/5 
TMZ 94 9 2 0/5 
Combination 91 9.5 2.5 (25%) 0/5 
  
    
D384Med Control 100 16  0/5 
AG-014699 96 20 4 0/5 
TMZ 97 44.5 28.5 1/5 
Combination 90 62 46 (61%) 1/5 
  
Legends to figures 
Figure 1. Protein expression levels of PARP-1 and proteins related to 
temozolomide sensitivity / resistance in medulloblastoma cell lines. Expression 
levels of alpha-tubulin (control) are also shown. Protein expressionwas determined 
for 50 µg of whole cell lysate by western blot analysis and visualised by chemo-
luminescence. D425 cells have no detectable MGMT and D283 no detectable MLH-1 
and minimal PMS2 consistent with MGMT and Mismatch repair deficiency 
respectively whereas D384 are proficient for both.  
 
 
Figure 2. Chemosensitisation to TMZ by AG-014699 in vitro in medulloblastoma 
cell lines. A-C. Growth inhibition of D425Med, D283Med and D384Med cells, 
determined by XTT assay following a 6-day exposure to TMZ either alone (solid 
triangles) or with 0.4 µM AG-014699 (open triangles). Data are shown normalized to 
0.5% DMSO or 0.4 µM AG-014699 controls, respectively. A single representative 
replicate for TMZ ± 0.4 µM AG-014699 in D425Med (A), D283Med (B) and D384Med 
(C) cells (± 95% confidence intervals (CI)) is shown.  
 
Figure 3. AG-014699 pharmacokinetics and PARP-1 inhibition in mouse brain 
and medulloblastoma xenograft. Following a single (i) or the last of four daily 
doses (ii) of AG-014699 (1 mg/kg, i.p.), samples were taken and tissues harvested at 
the indicated times post-administration: (A) Concentration of AG-014447 in plasma 
(solid triangle), brain (open circle) and D283Med xenograft homogenates (solid 
circle) from tumour-bearing mice.  Corresponding PARP-1 activity in D283Med 
xenograft homogenates (B) and the brain (C) is shown. Concentrations of AG014447 
are given as the mean (± 95% CI) from three tumour-bearing mice per time point, 
PARP activity measurements are given as individual values with the horizontal lines 
indicating the mean value.   
 
Figure 4.  Enhancement of TMZ efficacy by AG-014699 in in vivo models of 
medulloblastoma. Growth of D425Med (A), D283Med (B) or D384Med (C) tumour 
xenografts over a 100 day period, following daily treatment for 5 days with vehicle 
control alone (solid circles), AG-014699 alone (1 mg/kg, open circles), TMZ alone (68 
mg/kg, solid triangles) or TMZ (68 mg/kg) + AG-014699 (1 mg/kg) (open triangles). 
Dashed horizontal line corresponds to RTV4. Data are median of 5 mice/group until 
first humane killing due to tumour burden. 
  
 
  
 
  
 
  
 
0 10 20 30 40 50 60 70
0
2
4
6
8
10
Time (days)
Tu
m
o
u
r 
gr
o
w
th
: 
M
ed
ia
n
 
R
TV
A 
C 
B 
Figure 4 
0 20 40 60 80 100
0
2
4
6
8
10
Time (days)
Tu
m
o
u
r 
gr
o
w
th
: 
M
e
di
a
n
 
RT
V
0 5 10 15 20 25
0
2
4
6
8
10
Time (days)
Tu
m
o
u
r 
gr
o
w
th
: 
M
ed
ia
n
 
R
TV
